Finally, our established PDX models could serve as a functional validation of EphA2’s relevance in the progression of osteosarcoma, Ewing’s sarcoma and chondrosarcoma for further testing EphA2-targeting strategies in vivo, in different histotypes and at various disease stages (i.e., localized vs. metastatic). The gene discussed is EPHA2; the disease is osteosarcoma.